Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers.

摘要: Microalbuminuria is an issue of great concern in hypertensive patients owing to its close relation with cardiovascular morbidity and mortality. Treatment should aim reduce microalbuminuria the normal range. Drugs that block renin-angiotensin system have specific antiproteinuric properties, but more than one drug needed achieve blood pressure control most cases. The this study was compare effects adding manidipine treatment essential hypertension persistent albuminuria, despite full-dose a blocker on urinary albumin excretion (UAE) after 24 weeks therapy. Patients diabetes renal insufficiency were excluded. At baseline, UAE 155.1 +/- 12/87.76 11 mmHg 293.19 285 mg/g, respectively. end, 137.1 13.1/77.24 10.4 (p < 0.001 vs baseline). reduced by 45% 161.52 163 mg/g No correlations found between systolic reduction (Pearson's R = -0.034; p not significant) nor estimated glomerular filtration rate -0.0056; significant). patient withdrew from side effects. In conclusion, resulted large rates, appeared be independent degree or changes rate. Our data supports added value microalbuminuria.